(100 pts) 1.Are antimitotics still relevant as a potent chemotherapeutic strategy?

2.How to improve the selectivity of antimitotics towards cancer cells without off-site(s) targeting?

3.Can the balance of therapeutic benefits and reversible side effects be struck in combinatorial treatments consisting of multiple antimitotics targeting different stages of mitosis?

4.What about multi-phasic combinatorial therapies encompassing antimitotics, DNA-damaging agents (including antimetabolites and antibiotics) and/or antiangiogenic drugs?